Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Jul;20(1):27–35. doi: 10.1111/j.1365-2125.1985.tb02794.x

A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.

P J Manhem, S G Ball, J J Morton, G D Murray, B J Leckie, R Fraser, J I Robertson
PMCID: PMC1400639  PMID: 2992562

Abstract

The effect of different oral doses of HOE 498, a new non-sulphydryl containing converting enzyme inhibitor, was investigated in a double-blind, placebo-controlled study in normotensive volunteers. Dose-related reductions in serum converting enzyme activity, plasma angiotensin II and aldosterone were seen, greater at 4 h than at 12 h after drug ingestion. Converse dose-related increases in blood angiotensin I and plasma active renin concentration occurred. Falls of angiotensin II were as great with 20 mg as with 50 mg of HOE 498, although the effect was more prolonged with 50 mg. The reductions in concentrations of plasma angiotensin II and serum converting enzyme activity and the increases in plasma renin concentration were correlated with the concentration of HOE 498 - diacid in plasma. Dose-related falls in both supine and erect blood pressure were maximal 2-3.5 h after dosing. Pulse rate increased marginally but insignificantly in the supine; slightly and significantly in the upright position, concomitantly with the blood pressure reduction at all doses of active drug. We conclude that effects of single doses of HOE 498 on the renin-angiotensin system are maximal within 4 h, but are still apparent after 24 h. Thus it is likely that once daily administration will be adequate for treatment of high blood pressure in patients.

Full text

PDF
27

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABLAD B. Site of action of hydralazine and dihydralazine in man. Acta Pharmacol Toxicol (Copenh) 1959;16:113–128. [PubMed] [Google Scholar]
  2. Atkinson A. B., Brown J. J., Cumming A. M., Fraser R., Lever A. F., Leckie B. J., Morton J. J., Robertson J. I., Davies D. L. Captopril in the management of hypertension with renal artery stenosis: its long-term effect as a predictor of surgical outcome. Am J Cardiol. 1982 Apr 21;49(6):1460–1466. doi: 10.1016/0002-9149(82)90361-7. [DOI] [PubMed] [Google Scholar]
  3. Atkinson A. B., Morton J. J., Brown J. J., Davies D. L., Fraser R., Kelly P., Leckie B., Lever A. F., Robertson J. I. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. Br Heart J. 1980 Sep;44(3):290–296. doi: 10.1136/hrt.44.3.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Atkinson A. B., Robertson J. I. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836–839. doi: 10.1016/s0140-6736(79)92186-x. [DOI] [PubMed] [Google Scholar]
  5. Ball S. G., Robertson J. I. A need for new converting enzyme inhibitors? Br Med J (Clin Res Ed) 1985 Jan 19;290(6463):180–181. doi: 10.1136/bmj.290.6463.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brunner D. B., Desponds G., Biollaz J., Keller I., Ferber F., Gavras H., Brunner H. R., Schelling J. L. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981 May;11(5):461–467. doi: 10.1111/j.1365-2125.1981.tb01151.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brunner H. R., Gavras H., Waeber B., Kershaw G. R., Turini G. A., Vukovich R. A., McKinstry D. N., Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979 Jan;90(1):19–23. doi: 10.7326/0003-4819-90-1-19. [DOI] [PubMed] [Google Scholar]
  8. Chinn R. H., Düsterdieck G. The response of blood pressure to infusion of angiotensin II: relation to plasma concentrations of renin and angiotensin II. Clin Sci. 1972 Apr;42(4):489–504. doi: 10.1042/cs0420489. [DOI] [PubMed] [Google Scholar]
  9. Dargie H. J., Ball S. G., Atkinson A. B., Robertson J. I. Converting enzyme inhibitors in hypertension and heart failure. Br Heart J. 1983 Apr;49(4):305–308. doi: 10.1136/hrt.49.4.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dollery C. T. Safety and efficacy of enalapril. Summing up the evidence. J Hypertens Suppl. 1983 Oct;1(1):155–157. [PubMed] [Google Scholar]
  11. Fraser R., Guest S., Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. doi: 10.1042/cs0450411. [DOI] [PubMed] [Google Scholar]
  12. Hajdú P., Schmidt D., Bomm M., Hack L., Keller A. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine. Arzneimittelforschung. 1984;34(10B):1431–1435. [PubMed] [Google Scholar]
  13. Hodsman G. P., Brown J. J., Cumming A. M., Davies D. L., East B. W., Lever A. F., Morton J. J., Murray G. D., Robertson I., Robertson J. I. Enalapril in the treatment of hypertension with renal artery stenosis. Br Med J (Clin Res Ed) 1983 Nov 12;287(6403):1413–1417. doi: 10.1136/bmj.287.6403.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hodsman G. P., Brown J. J., Cumming A. M., Davies D. L., East B. W., Lever A. F., Morton J. J., Murray G. D., Robertson J. I. Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. J Hypertens Suppl. 1983 Oct;1(1):109–117. [PubMed] [Google Scholar]
  15. Hodsman G. P., Zabludowski J. R., Zoccali C., Fraser R., Morton J. J., Murray G. D., Robertson J. I. Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol. 1984 Mar;17(3):233–241. doi: 10.1111/j.1365-2125.1984.tb02337.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kaneko Y., Ikeda T., Takeda T., Ueda H. Renin release during acute reduction of arterial pressure in normotensive subjects and patients with renovascular hypertension. J Clin Invest. 1967 May;46(5):705–716. doi: 10.1172/JCI105571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lee W. B., Ismay M. J., Lumbers E. R. Mechanisms by which angiotensin II affects the heart rate of the conscious sheep. Circ Res. 1980 Aug;47(2):286–292. doi: 10.1161/01.res.47.2.286. [DOI] [PubMed] [Google Scholar]
  18. Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med. 1975 Sep;59(3):365–372. doi: 10.1016/0002-9343(75)90395-2. [DOI] [PubMed] [Google Scholar]
  19. Lumbers E. R., McCloskey D. I., Potter E. K. Inhibition by angiotensin II of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog. J Physiol. 1979 Sep;294:69–80. doi: 10.1113/jphysiol.1979.sp012915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. MacGregor G. A., Markandu N. D., Bayliss J., Roulston J. E., Squires M., Morton J. J. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. Br Med J (Clin Res Ed) 1981 Aug 8;283(6288):401–403. doi: 10.1136/bmj.283.6288.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. MacGregor G. A., Markandu N. D., Roulston J. E., Jones J. C., Morton J. J. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature. 1981 May 28;291(5813):329–331. doi: 10.1038/291329a0. [DOI] [PubMed] [Google Scholar]
  22. Manhem P., Bramnert M., Hulthén U. L., Hökfelt B. The effect of captopril on catecholamines, renin activity, angiotensin II and aldosterone in plasma during physical exercise in hypertensive patients. Eur J Clin Invest. 1981 Oct;11(5):389–395. doi: 10.1111/j.1365-2362.1981.tb02001.x. [DOI] [PubMed] [Google Scholar]
  23. Millar J. A., Derkx F. H., McLean K., Reid J. L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol. 1982 Sep;14(3):347–355. doi: 10.1111/j.1365-2125.1982.tb01990.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Millar J. A., Leckie B. J., Morton J. J., Jordan J., Tree M. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta. 1980 Feb 14;101(1):5–15. doi: 10.1016/0009-8981(80)90050-9. [DOI] [PubMed] [Google Scholar]
  25. Niarchos A. P., Pickering T. G., Case D. B., Sullivan P., Laragh J. H. Role of the renin-angiotensin system in blood pressure regulation. The cardiovascular effects of converting enzyme inhibition in normotensive subjects. Circ Res. 1979 Dec;45(6):829–837. doi: 10.1161/01.res.45.6.829. [DOI] [PubMed] [Google Scholar]
  26. Scroop G. C., Lowe R. D. Efferent pathways of the cardiovascular response to vertebral artery infusions of angiotensin in the dog. Clin Sci. 1969 Dec;37(3):605–619. [PubMed] [Google Scholar]
  27. WILKINSON E. L., BACKMAN H., HECHT H. H. Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline). J Clin Invest. 1952 Oct;31(10):872–879. doi: 10.1172/JCI102674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Waite M. A. Measurement of concentrations of angiotensin I in human blood by radioimmunoassay. Clin Sci. 1973 Jul;45(1):51–64. doi: 10.1042/cs0450051. [DOI] [PubMed] [Google Scholar]
  29. Wenting G. J., Man in't veld A. J., Woittiez A. J., Boomsma F., Laird-Meeter K., Simoons M. L., Hugenholtz P. G., Schalekamp M. A. Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J. 1983 Jan;49(1):65–76. doi: 10.1136/hrt.49.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES